2018
Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction.
Chiang AC, Lake J, Sinanis N, Brandt D, Kanowitz J, Kidwai W, Kortmansky J, LaSala J, Orell J, Sabbath K, Tara H, Engelking C, Shomsky L, Fradkin M, Adelson K, Uscinski K, Vest K, Lyons C, Lemay A, Lopman A, Fuchs CS, Lilenbaum R. Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction. JCO Oncology Practice 2018, 14: e823-e833. PMID: 30537462, DOI: 10.1200/jop.18.00419.Peer-Reviewed Original ResearchConceptsQuality of carePatient satisfactionClinical trialsSmilow Cancer HospitalUS academic centersCommunity oncology practicesPress Ganey scoresCenter physiciansAntineoplastic treatmentCancer HospitalOffice visitsCancer practiceTumor stagingCare centerOncology practiceTumor boardClinical careAcademic centersCase presentationPractice sitesCareCore measuresTrialsCommunity practiceClinical integration
2016
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial
Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona-Calero M, Ma CX, Hershman D, Baar J, Klein P, Cigler T, Budd GT, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D. Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial. Npj Breast Cancer 2016, 2: 16037. PMID: 28721390, PMCID: PMC5515340, DOI: 10.1038/npjbcancer.2016.37.Peer-Reviewed Original ResearchProgression-free survivalSelective estrogen receptor downregulatorsMetastatic breast cancerER-positive metastatic breast cancerMedian progression-free survivalArm ABreast cancerArm BHormone receptor-positive metastatic breast cancerRandomized phase II trialPhase II trialEstrogen receptor downregulatorsProteasome inhibitor bortezomibPFS ratesII trialConsortium TrialHazard ratioPostmenopausal womenPreclinical modelsInhibitor bortezomibBortezomibCancerProteasome inhibitorsAdditional evaluationTrialsTesting Violations of the Exponential Assumption in Cancer Clinical Trials with Survival Endpoints
Han G, Schell MJ, Zhang H, Zelterman D, Pusztai L, Adelson K, Hatzis C. Testing Violations of the Exponential Assumption in Cancer Clinical Trials with Survival Endpoints. Biometrics 2016, 73: 687-695. PMID: 27669414, PMCID: PMC6093291, DOI: 10.1111/biom.12590.Peer-Reviewed Original Research
2014
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2-positive breast cancer.
Kalinsky K, Chi D, Lee S, Adelson K, Crew K, Chuang E, Makower D, Hershman D, Califano A, Silva J, Maurer M. Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2-positive breast cancer. Journal Of Clinical Oncology 2014, 32: tps666-tps666. DOI: 10.1200/jco.2014.32.15_suppl.tps666.Peer-Reviewed Original Research